BioForce Nanosciences Reports Record Revenues, First Quarter 2007 Financial Results.

AMES, Iowa -- BioForce Nanosciences Holdings, Inc. (OTCBB:BFNH) today reported its first quarter 2007 results. Revenue was $358,755, which represents the highest quarterly revenue in company history, as compared to revenue of $201,376 in the first quarter of 2006. Net loss for the first quarter of 2007 was $923,317, or $0.04 per basic and diluted share, as compared with a net loss of $1,252,562, or $0.05 per basic and diluted share, for the first quarter of 2006.

Non-GAAP net loss for the first quarter of 2007 was $605,858, or $0.03 per basic and diluted share, as compared to a non-GAAP net loss of $261,298, or $0.01 per basic and diluted share for the first quarter of 2006. Non-GAAP financial measures exclude stock-based compensation expense and interest expense recorded as a result of a beneficial conversion feature of convertible debt that was retired during 2006. The reconciliation between GAAP net loss per share and non-GAAP net loss per share is set forth at the end of this press release.

Dr. Eric Henderson, BioForce's CEO and founder, said, "Marketplace acceptance of our flagship instrument, the Nano eNabler[TM] system, has reached a new level with the sales during the first quarter to the University of Limerick (Ireland), Louisiana Tech University and the National Nanotechnology Laboratory of National Research Council (Italy). Nano eNabler systems are being used to pursue scientific advancement in a wide range of applications within the biotechnology universe, including the development of various diagnostic tests and therapeutic agents. Our recent successes with sales and customer approval have been an incredible reward."

"With a strong start to the year, BioForce is on schedule to meet our business objectives for 2007 and achieve our vision of becoming an industry leader in bionanotechnology," said Dr. Henderson. "We will accomplish this by executing our "practical nanotechnology" strategy that embraces both the long-term promise of nanotechnology, and critically, the near term needs of the industry."

About BioForce Nanosciences, Inc.

BioForce Nanosciences Holdings, Inc. (OTCBB:BFNH) is a developer of nanotechnology instruments, consumables, and applications for the life sciences industry. The Nano eNabler system is a molecular printer that rapidly and precisely delivers liquids to surfaces such as silicon chips in droplets that are ten billion times smaller than a drop of blood. It is through our instrumentation success that BioForce can pursue applications. The patented virus detection chip embodied in the ViriChip[TM] platform is one such application. The ViriChip technology is sensitive and specific enough to detect a variety of different pathogens. For more information, visit www.bioforcenano.com.

[TABLE OMITTED]
[TABLE OMITTED]
[TABLE OMITTED]
[TABLE OMITTED]

Use of Non-GAAP Financial Information

To supplement our consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP), we provide investors with certain non-GAAP financial measures, including non-GAAP net income (loss) and non-GAAP basic and diluted net income (loss) per share. These non-GAAP measures exclude the effect of stock compensation expense for employee stock options and stock warrants associated with the application of SFAS 123R, and interest expense recorded as a result of a beneficial conversion feature of convertible debt that was retired during 2006. The presentation of these non-GAAP financial measures is not meant to be considered in isolation or as a substitute for net income (loss) or basic and diluted net income (loss) per share prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. We believe that these non-GAAP measures, when shown in conjunction with the corresponding GAAP measures, are used by and are useful to investors and other users of our financial statements in evaluating our operating results and comparative trends, as well as in facilitating comparisons with our historical operating results. The non-GAAP results are an indicator of our baseline performance before gains, losses or other charges that are considered by us to be outside of our core operating results and are excluded by us for purposes of evaluating performance against internal budgets and in making operational decisions. In addition, these non-GAAP results are among the primary indicators we use as a basis for our planning and forecasting of future periods.

There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables above.

This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in the Company's most recent filings with the Securities and Exchange Commission. The Company's actual results could differ materially from such forward-looking statements. We assume no duty to update these statements at any future date.